by Matthew Johnson | Jan 31, 2019 | Federal Circuit Appeal, Pharmaceutical, Standing
By Mike Lavine and Matt Johnson Mylan Pharmaceuticals, Inc. petitioned for inter partes review (IPR) of U.S. Patent No. 6,858,650 (the “‘650 Patent”), which is owned by UCB Pharma GmbH (“UCB”) and is directed to chemical derivatives of a drug for treating urinary...
by Matthew Johnson | Jan 28, 2019 | PGR
By Sue Gerber and Matt Johnson The America Invents Act (“AIA”), also called the Patent Reform Act of 2011, was enacted to overhaul the U.S. patent system and harmonize the domestic patent laws with those in the rest of the world. The AIA also created new procedures...
by Matthew Johnson | Jan 17, 2019 | PTAB News
Jones Day was recognized by the legal publication Law360 for its 2018 “Practice Groups of the Year” awards in the Intellectual Property and Product Liability categories. Now in their ninth year, the awards “honor the law firms behind the litigation...
by Matthew Johnson | Jan 3, 2019 | Amendment Practice, PTAB Trial Basics
By Levent Herguner and Matt Johnson – On November 30, 2018, the PTAB filed an opinion addressing two procedural issues in Aver Information Inc. v. Pathway Innovations and Technologies, Inc., Case IPR2017-02108, including failure to meet spacing requirements and...
by Matthew Johnson | Dec 31, 2018 | Estoppel
By Marlee Hartenstein and Matt Johnson – Assignor estoppel is an equitable doctrine that prevents a party who assigns a patent to another from later challenging the validity of the assigned patent. As reported in a prior post, the Federal Circuit recently...
